Sinobioway Medicine's subsidiary Tianjin Sinobioway was suspended from production and sales by the Tianjin Municipal Drug Administration on April 22, 2025. Tianjin Sinobioway mainly engages in the production and sales of human interferon drugs, achieving an operating income of 216.5683 million yuan and a net profit of -14.0037 million yuan in 2024, accounting for 60.09% of the company's operating income and 9.8% of the consolidated net profit, respectively. This suspension has a significant impact on the company's operations

Sinobioway Medicine: The controlling subsidiary Tianjin Sinobioway was subjected to risk control measures of suspension of production and sales by the Tianjin Municipal Drug Administration on April 22, 2025. Tianjin Sinobioway mainly engages in the production and sales of human interferon drugs. In 2024, Tianjin Sinobioway achieved operating revenue of RMB 216.5683 million and a net profit of RMB -14.0037 million, accounting for 60.09% of the company's operating revenue and 9.8% of the consolidated net profit during the same period, making it an important subsidiary of the company. This suspension of production and sales will have a significant impact on the company's production and operations